GACM
REGN icon

Green Arrow Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Green Arrow Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-15,000
Closed -$3.37M – 296
2013
Q2 		$3.37M Buy
+15,000
New +$3.49M 0.27% 116

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Green Arrow Capital Management's REGN Position: Q3 2013 in Review

Green Arrow Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2013, closing a stake of 15,000 shares — an estimated $3.37M sold.

Green Arrow Capital Management first reported a position in REGN in Q2 2013 and held it in 1 quarter. The position peaked at $3.37M in Q2 2013. 414 funds tracked by Wall St. Rank hold REGN as of Q3 2013.

  • Green Arrow Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • Green Arrow Capital Management sold 15,000 Regeneron Pharmaceuticals shares in Q3 2013, an estimated $3.37M.
  • Green Arrow Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • Green Arrow Capital Management's Regeneron Pharmaceuticals position peaked at $3.37M in Q2 2013.
  • 414 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2013.

Based on Green Arrow Capital Management's 13F filing for Q3 2013, filed 14 Nov 2013.